QuickView for abatacept (compound)

LEA29Y; LEA 29Y; CD152 antigen; CTLA-4 (antigen) (29-tyrosine,104-glutamic acid) (human extracellular domain-containing fragment) fusion protein with immunoglobulin G1 (human monoclonal Fc domain-containing fragment), bimol. (120->120?)-disulfide; cytotoxic T-lymphocyte antigen 4; BMS-224818; Belatacept; BMS 224818; BMS224818; Belatacept [USAN].
show more »

LEA29Y; LEA 29Y; CD152 antigen; CTLA-4 (antigen) (29-tyrosine,104-glutamic acid) (human extracellular domain-containing fragment) fusion protein with immunoglobulin G1 (human monoclonal Fc domain-containing fragment), bimol. (120->120?)-disulfide; cytotoxic T-lymphocyte antigen 4; BMS-224818; Belatacept; BMS 224818; BMS224818; Belatacept [USAN]; 706808-37-9
show less «

CTLA4-IgG4m; RG-1046; CTLA4Ig; RG1046; CTLA4-Ig; RG-2077; RG2077; CTLA4IgG4m

Abatacept is the first in a new class of drugs known as Selective Co-stimulation Modulators. Known as a recombinant fusion protein, the drug consists of the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc portion of human immunoglobulin G₁ (IgG₁. The Fc portion of the ...
show more »

Abatacept is the first in a new class of drugs known as Selective Co-stimulation Modulators. Known as a recombinant fusion protein, the drug consists of the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) linked to a modified Fc portion of human immunoglobulin G₁ (IgG₁. The Fc portion of the drug consists of the hinge region, the C_H2 domain, and the C_H3 domain of IgG₁. Although there are multiple pathways and cell types involved in the pathogenesis of rheumatoid arthritis, evidence suggests that T-cell activation may play an important role in the immunopathology of the disease. Ordinarily, full T-cell activation requires binding of the T-cell receptor to an antigen-MHC complex on the antigen-presenting cell as well as a co-stimulatory signal provided by the binding of the CD28 protein on the surface of the T-cell with the CD80/86 proteins on the surface of the antigen-presenting cell. CTLA4 is a naturally occurring protein which is expressed on the surface of T-cells some hours or days after full T-cell activation and is capable of binding to CD80/86 on antigen-presenting cells with much greater affinity than CD28. Binding of CTLA4-Ig to CD80/86 provides a negative feedback mechanism which results in T-cell deactivation. Abatacept was developed by Bristol-Myers-Squibb and is licensed in the US for the treatment of Rheumatoid Arthritis in the case of inadequate response to anti-TNF-alpha therapy.
show less «

Abatacept is a selective costimulation modulator, like CTLA-4, the drug has shown to inhibit T-cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Blockade of this interaction has been shown to inhibit the delivery of the second co-stimulatory signal required for optimal activation of T-cells. This re...
show more »

Abatacept is a selective costimulation modulator, like CTLA-4, the drug has shown to inhibit T-cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Blockade of this interaction has been shown to inhibit the delivery of the second co-stimulatory signal required for optimal activation of T-cells. This results in the inhibition of autoimmune T-Cell activation that has been implcated in the pathogenesis of rheumatoid arthritis.
show less «